Project Grant 2227373
Award Date
7/1/22
Completion Date
6/30/23
Dollars Obligated
$100K
Federal Agency
National Science Foundation
Federal Grant Program
47.084
Assistance Type
Project Grant
Place of Performance
Iowa City, IA 52242, USA
Similar Awards
This $332,179 Project Grant awarded by the National Eye Institute (CFDA 93.867 Vision Research) supports the development of nanobarrier contact lenses that can provide sustained delivery of the drug cysteamine to treat the ocular complications of cystinosis. The lenses are designed to replace the current 8-times daily eye drop regimen, improving patient compliance and reducing side effects from the preservatives and acidic pH in the eye drops. The project aims to demonstrate the lenses can...
This $201,825 Project Grant award from the National Eye Institute (NEI) Vision Research program (CFDA 93.867) supports research to evaluate the use of condensin inhibitors as a potential topical treatment for Pseudomonas aeruginosa bacterial eye infections. The lead investigator, Dr. Valentin Rybenkov at the University of Oklahoma, will collaborate with Dr. Michelle Callegan at the University of Oklahoma Health Sciences Center to conduct in vivo studies examining the toxicity, corneal...
This Project Grant award from the National Eye Institute (CFDA 93.867 - Vision Research) provides $588,731 to The University of Iowa to investigate the role of ferroptosis, a type of oxidative cell death, in the progression of Fuchs Endothelial Corneal Dystrophy (FECD). The key research objectives are to: 1) Define the interplay between FECD-associated corneal guttae and ferroptosis, 2) Determine how ultraviolet-A light exposure mediates ferroptosis in FECD, and 3) Develop drug therapies to...
This Cooperative Agreement award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) provides $998,356 to Revive Biotechnology Inc. to develop an oxygen nanobubble platform technology for treating ischemic retinal diseases. The project aims to secure an Investigational New Drug (IND) indication for the treatment of central retinal artery occlusion (CRAO), a leading cause of sudden vision loss, and then expand the technology to...
The National Eye Institute (NEI) awarded a $225,772 Project Grant (CFDA 93.867 - Vision Research) to The Research Foundation For The State University Of New York, doing business as Stony Brook University, to develop a terahertz time-domain spectroscopy (THz-TDS) imaging system that can accurately measure and map corneal hydration gradients. The project aims to: Determine the accuracy of the THz-TDS corneal scanner in measuring hydration levels in corneal phantoms and ex vivo models. Evaluate the...
This Project Grant award from the National Eye Institute (CFDA 93.867 Vision Research) supports the development and validation of a nanoparticle-based therapy called TRE-D-DASA to treat corneal neovascularization (CONV), a sight-threatening condition characterized by abnormal blood vessel growth in the cornea. The $482,067 award will fund research to: 1) synthesize and characterize the TRE-D-DASA conjugate and a fluorescent version for imaging; 2) assess the biodistribution, pharmacokinetics,...
The National Science Foundation (NSF) awarded a $274,416 Project Grant under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to Biolattice Ophthalmics, Inc. (doing business as Biolattice LLC) on December 1, 2023. The award supports the development of a novel acellular polymer membrane for use as a cornea substitute, with the goal of providing a true alternative to donor cornea for full thickness cornea replacement. The artificial cornea aims to offer a biocompatible,...
This Project Grant award from the National Eye Institute (NEI) under the Vision Research program (CFDA 93.867) provides $1,066,178 to Tavo Biotherapeutics, Inc. (operating as Oculo Therapy LLC) to support late-stage preclinical development and GMP production of a novel extended-release intraocular pressure (IOP)-lowering formulation for the treatment of glaucoma. The funding will enable critical IND-enabling studies for this first-in-class drug candidate using the FDA-approved drug pregabalin as...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $275,000 to Teardx, LLC will fund the development of a rapid, point-of-care diagnostic test to accurately detect ocular herpes simplex virus (HSV-1) infections. The project aims to create a user-friendly, minimally invasive sampling tool and assay that can be used by eye specialists and urgent care clinicians to quickly screen for active HSV-1 infections, which are a leading cause...
This Project Grant award from the National Eye Institute (NEI), under the federal Vision Research program (CFDA 93.867), aims to develop a refillable micromachined lens capsule-based drug delivery device for extended intraocular delivery of biologics and immune-modulating peptides to treat non-infectious uveitis. The $257,785 award to The Leland Stanford Junior University (Stanford University) will support research to characterize and control the release of adalimumab and a novel...